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Paulo Afonso Mei1, Maria Augusta Montenegro2, 
Marilisa M. Guerreiro3, Carlos A.M. Guerreiro4
ABSTRACT - Objective: To investigate the occurrence of adverse effects of antiepileptic drugs (AED) in
c h ronic epileptic patients in mono or polytherapy. Method: We evaluated consecutive patients that met
the following inclusion criteria: age of 18 years or older, diagnosis of epilepsy for at least one year, stable
dose of AED for at least three months. Patients were asked if they had any adverse event related to the
AED. After that, they were interviewed according to a detailed semi-stru c t u re questionnaire. We also
assessed specifically the adverse events in the last four weeks. The data were analyzed regarding the use
of monotherapy x polytherapy, and the presence of probable depression (score >15) according to the Center
for Epidemiologic Studies Depression Scale. Results: Sixty-five patients were evaluated, 35 women, mean
age 38.3 years; 35 patients were in use of monotherapy and 35 in polytherapy. Only 45 (69.2%) patients
spontaneously re p o rted adverse effects. After the formal questionnaire, 63 (97%) patients re f e rred expe-
riencing an adverse event (p<0.001). Seventeen men had adverse events, as opposed to 28 women (p=0.042).
When the last four weeks were evaluated, patients with probable depression presented adverse events
m o re frequently (p<0.0001). Conclusion: Our data suggest that adverse events are highly prevalent when
a detailed questionnaire is applied and that depression may aggravate the number and intensity of side
effects in patients using AEDs. 
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Farmacovigilância em pacientes com epilepsia em uso de drogas antiepilépticas
RESUMO - Objetivo: Investigar a ocorrência de efeitos adversos das drogas antiepilépticas (DAE) em pacientes
com epilepsia crônica tanto em mono quanto em politerapia. Método: Avaliamos consecutivamente os
pacientes que preencheram os seguintes critérios de inclusão: idade igual ou superior a 18 anos, diagnós-
tico de epilepsia por no mínimo um ano, doses estáveis de DAE por no mínimo três meses. Os pacientes
foram instados a responder espontaneamente sobre a presença de efeitos colaterais das DAE. Após isto,
um questionário formal sobre eventos adversos foi aplicado. Também avaliamos especificamente a pre-
sença de queixas nas últimas quatro semanas. Os dados foram analisados levando-se em conta o uso de
mono ou politerapia e a presença ou não de provável depressão (índice >15) segundo o CES-D. R e s u l t a d o s :
Sessenta e cinco pacientes foram avaliados, 35 mulheres, idade média 38,3 anos; 35 pacientes estavam em
uso de monoterapia e 35 em politerapia. Somente 45 (69,2%) pacientes espontaneamente registraram a
p resença de efeitos adversos. Após o questionário formal, 63 (97%) pacientes tiveram queixas (p<0,001).
Dezessete homens e 28 mulheres re p o rtaram eventos adversos (p=0,042). Quando as últimas quatro sema-
nas foram analisadas, os pacientes com provável depressão relataram mais freqüentemente a presença de
efeitos adversos (p<0,0001). Conclusão: Nossos dados sugerem que efeitos adversos são altamente pre v a-
lentes quando um questionário detalhado é aplicado e que depressão pode agravar o número e a inten-
sidade de eventos adversos em pacientes com epilepsia utilizando DAE. 
PALAVRAS-CHAVE: drogas antiepilépticas, farmacovigilância, epilepsia, depressão, eventos adversos. 
Most patients with epilepsy depend on the med-
ical treatment with antiepileptic drugs (AED) to
achieve control of their seizures, which occurs in
a round 60-70% of the patients1. A third of the epilep-
tic patients do not obtain seizure control with AED
d rugs. For them other treatment options are indicat-
ed, eventually surg e ry. Chronic use of AED may be
associated with several systemic and central nerv o u s
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system adverse events2 - 1 5. Polytherapy is sometimes
used in re f r a c t o ry epilepsy despite significant incre a s e
in the number of the side eff e c t s1 6 , 1 7. More o v e r, there
is a considerable incidence of co-morbidity among
epileptic patients, such as depression, mainly in those
with re f r a c t o ry epilepsy1 8 - 2 1. Quality of life is associ-
ated with seizure control, presence of depression and
with adverse AED events as well22. 
Adverse effects are highly prevalent in the med-
ical treatment of epilepsy. For instance, carba-
mazepine (CBZ) is one of the main drugs used for
focal and generalized seizures, and may cause seda-
tion in 40% of the patients14. 
The aim of this study was to investigate the occur-
rence of adverse events of AED in chronic epileptic
patients in mono or polytherapy. We collected spon-
taneous complaints and compared with a detailed
semi-structured questionnaire. 
METHOD
This study was conducted at the epilepsy clinic of our
university hospital from June 2003 to December 2004. 
We evaluated consecutive patients that met the follow-
ing inclusion criteria: aged 18 years or older, diagnosis of
epilepsy for at least one year, stable dose of AED for at least
t h ree months, signature of informed consent. Exclusion cri-
teria: uncertain diagnosis of epilepsy, patients with cogni-
tive impairment, change in AED dose in the last thre e
months, refuse to sign the informed consent. 
Patients were asked if they had any adverse event re l a t-
ed to the AED. After that, re g a rdless of the answer, they
w e re interviewed according to a detailed semi-stru c t u re
q u e s t i o n n a i re about the presence of adverse events asso-
ciated with the AED, based on literature2 2 and adapted to
Portuguese colloquial terms by the authors. 
We also assessed specifically the adverse events in the
last four weeks. They were rated as 1 to 4 points, accord-
ing to the following scale: 1 - absent, 2 - rare, 3 - someti-
mes/mild, 4 - frequent/always22. 
The data was analyzed re g a rding the use of monother-
apy versus polytherapy, and the presence of pro b a b l e
d e p ression (score >15) according to the Center for
Epidemiologic Studies Depression Scale - CES-D2 3. This scale
allows to differentiate three groups of patients according
to the score: if the score is 22 or higher, the patient may
be suffering from a major depression; if the score is 15 to
21, the patient may be suffering from mild to moderate
d e p ression; if the score is below 15, this test does not indi-
cate that the patient is depressed. The reason to choose
this scale is that it has been used in the literature to eval-
uate epileptic patient during antiepileptic drug tre a t m e n t2 2.
Statistical analysis was perf o rmed using the chi-square
test, Fisher exact test and Student t-test. 
RESULTS
Sixty-five patients were evaluated, 35 women,
ages ranging from 20 to 70 years-old (mean=38.3
years). Thirty patients were in use of monotherapy
and 35 in polytherapy. 
Table 1. Frequency of adverse events in the last four weeks versus since the beginning of the treatment.
Adverse event Patients in monotherapy Patients in polytherapy
Beginning of treatment Last four weeks Beginning of treatment Last four weeks
Emotional liability – 14 (46.7 %) – 17 (48.6 %)
Fatigue 14 (46.7 %) 15 (50 %) 15 (42.9 %) 18 (51.4 %)
Psychomotor agitation – 16 (53.3 %) – 19 (54.3 %)
Agressivity 4 (13.3 %) 11 (36.7 %) 4 (11.4 %) 10 (28.6 %)
Anxiety – 15 (50 %) – 15 (42,9 %)
Headache 3 (10 %) 8 (26.7 %) 2 (5.7 %) 17 (48.6 %)
Hair loss 4 (13.3 %) 5 (16.7 %) 11 (31.4 %) 9 (25.7 %)
Skin reactions 3 5 (16.7 %) 6 (17.1 %) 7 (20 %)
Diplopia or blurred vision 2 (6.7 %) 4 (13.3 %) 11 (31.4 %) 11 (31.4 %)
Dyspepsia – 11 (36.7 %) – 17 (48.6 %)
Gingival hypertrophy 6 (20%) 4 (13.3 %) 10 (28.6 %) 7 (20 %)
Tremor – 12 (40 %) – 11 (31.4 %)
Weight gain – 5 (16.7 %) – 3 (10 %)
Dizziness 5 (16.7 %) 6 (20 %) 9 (25.7 %) 11 (31.4 %)
Somnolence 14 (46.7 %) 16 (53.3 %) 11 (31.4 %) 11 (31. 4 %)
Memory impairment 11 (36.7 %) 14 (46.7 %) 13 (37.1 %) 23 (65.7 %)
Sleep disturbance – 10 (33.3 %) – 13 (37.1 %)
Lack of concentration – 10 (33.3 %) – 15 (42.9 %)
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When asked about the presence of adverse events,
only 45 (69.2%) patients answered positively.
H o w e v e r, after the formal questionnaire, 63 (97%)
patients re f e rred experiencing an adverse event re l a t-
ed to AEDs (p<0.001). Seventeen men had adverse
events, as opposed to 28 women (p=0.042). 
Table 1 shows the data for each symptom in
patients with monotherapy or polytherapy since the
introduction of the AED and in the last four weeks.
The Student t-test showed no diff e rence between
the presence of adverse events since the intro d u c-
tion of the AED either on monotheraphy (p=0.309)
or polytherapy (p=0.143).
We found that 19 patients in monotherapy had
adverse events, as opposed to 26 in polytherapy
(p=0.340). Table 2 shows the individual analysis for
each symptom, and only diplopia was more fre q u e n t
in patients with polytherapy.
Twenty-two patients had probable depre s s i o n
a c c o rding to the Center for Epidemiologic Studies
D e p ression Scale; and 18 of them presented adverse
events. From the 45 patients without depression, 27
had adverse events (p=0.115). However, when the
last four weeks were evaluated separately, patients
with probable depression presented adverse events
more frequently (p<0.0001, Table 3). 
DISCUSSION
The recognition of the most frequent side-eff e c t s
of AEDs helps clinical monitoring of medical tre a t-
ment of epilepsy. AEDs more commonly used in our
institution are carbamazepine, phenytoin, valpro a t e
Table 2. Adverse events in patients using one AED versus those on polytherapy. Data collected from a
detailed semi-structured questionnaire.
Adverse event Monotheraphy Politheraphy p
Yes No Yes No
Irritability 4 26 4 31 0.815
Dizziness 5 25 9 26 0.376
Memory impairment 11 19 13 22 0.968
Dispiritedness 14 16 15 20 0.758
Oversleeping 14 16 11 24 0.208
Unsteadiness 3 27 5 30 0.600
Headache 3 27 2 33 0.518
Diplopia 7 23 18 17 0.020
Change in apetite 8 22 10 25 0.864
Gingival bleeding or hypertrophy 6 24 10 25 0.423
Body hair growth 2 28 8 27 0.071
Alopecia 4 23 11 24 0.084
Unhapiness 12 18 11 24 0.471
Artralgia 1 29 3 32 0.380
Skin Rash/Allergy 3 27 6 29 0.405
Lack of libido 7 23 8 27 0.963
Difficulty of erection (men) 3 12 2 13 0.624
Table 3. Number of points attributed to adverse effects according to their intensity scored by each
patient in the last four weeks [scoring scale and CES-D (Center for Epidemiologic Studies Depre s s i o n
Scale) detailed in Method].
CES-D <15 # of patients CES-D > 15 # of patients
Scoring 1-20 03 (7.0%) Scoring 1-20 0 
Scoring 21-30 14 (32.5%) Scoring 21-30 1 (4.5%)
Scoring 31-40 19 (44.2%) Scoring 31-40 5 (22.7%)
Scoring greater than 40 07 (16.3%) Scoring greater than 40 16 (72.8%)
Total 43 (100.0%) Total 22 (100%)
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and clobazam. Our study revealed that hypersomnia,
dizziness, gastrointestinal distress and loss of mem-
ory are among the most frequent adverse events in
patients taking AED. Our result pointed out that
p roactive semi-stru c t u red query is important to detect
adverse events, otherwise not mentioned sponta-
neously by patients. This finding is in keeping with
other studies2 2 , 2 4. The number of adverse effects was
comparable between mono and polytherapy gro u p s
in our patients. However, when each side effect was
individually analyzed, diplopia was found to occur
m o re frequently in patients under polytherapy.
Several studies have indicated that the incidence of
adverse effects increase with the number of dru g s2 5 -
2 7. The small number of patients in this re s e a rch pro b-
ably explains because we found no diff e re n c e
between the two groups (monotherapy versus p o l y-
therapy).
We found that women re p o rted side effects more
f requently than men. Weight gain, cosmetic conse-
quences of the treatment and teratogenic effects of
AEDs - in those at childbearing age - usually bring
g reater concern for women1 2 , 2 8 , 2 9. There f o re, they
may be more aware of the possible side effects and
prone to report them. 
To the best of our knowledge, the Center for
Epidemiologic Studies Depression Scale - CES-D2 3 i s
not validated in our country; there f o re, we cannot
make definitive statements about its use and conclu-
sion in this work. In our study, when the last four
weeks were evaluated, patients with pro b a b l e
d e p ression presented adverse events more fre q u e n t-
ly than patients without depression. Co-morbidity in
epilepsy is a major issue nowadays and, for adults,
depression is one of the main conditions associated
with epilepsy3 0 - 3 2. Adverse AED effects and depre s-
sion may be the most important negative influences
on a person’s perception of their current health sta-
t u s2 2. The negative impact of depressive disorders in
the quality of life of patients with epilepsy demands
that their presence be investigated in every epilep-
tic patient33.
To conclude, our data suggest that adverse events
must be proactively identified through a systematic
q u e s t i o n n a i re and that depression may aggravate
the number and intensity of side effects in patients
using AEDs. 
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